Biogen Inks Deal With MAKScientific Daily Markets (blog) Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen has also been pretty active on the deal-making/acquisition front so far in 2012. |
